Immune-Onc Therapeutics Inc   Report issue

For profit Phase 1
Founded: Palo Alto CA United States (2016)

Organization Overview

First Clinical Trial
2020
NCT04372433
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Immune-Onc Therapeutics | Immune-Onc Therapeutics Inc

Active Ingredients

Drugs in Phase 1 Trials (3)

io-108 (2 trials)

io-202 (2 trials)

pembrolizumab (keytruda) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Leukemia, Myelomonocytic, Chronic (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 3